Škrott Zdeněk Ph.D.
About me
Junior researcher interested in protein homeostasis and degradation pathways in cancer and other diseases. Interested in microscopic techniques and live-cell imaging.
Author of 14 original scientific publications with over 600 SCI citations.
Journals
Actionable cancer vulnerability due to translational arrest, p53 aggregation and ribosome biogenesis stress evoked by the disulfiram metabolite CuET. Cell Death and Differentiation. 2023, ISSN: 1350-9047, PMID: 37142656,
A drug repurposing strategy for overcoming human multiple myeloma resistance to standard-of-care treatment. Cell Death & Disease. 2022, 13(3), 203, ISSN: 2041-4889, PMID: 35246527,
Intellectual property
MOLECULAR COMPLEX ASSEMBLY PARTICLES COMRISING BIS-R1, R2-DITHIOCARBAMATE-METAL COMPLEX AND A LIGAND, METHOD OF PREPARATION AND USE THEREOF "DISULFIRAM II" (Mistrík)
- Published Application EP 18199181.1 under EP 3636285 (15.4.2020)
- Published Application PCT/EP2019/077222 under WO 2020/074514 (16.4.2020)
- Patent: AU 2019358428. Granted: 4.8.2022. Ownership: Palacky University Olomouc. Inventors: Mistrík Martin, Bártek Jiří, Škrott Zdeněk, Džubák Petr, Hajdúch Marián
- Patent: JP 7220932. Granted: 3.2.2023. Ownership: Palacky University Olomouc. Inventors: Mistrík Martin, Bártek Jiří, Škrott Zdeněk, Džubák Petr, Hajdúch Marián
Status: Patents pending, Available
Open positions
1 Molecular and Translational Medicine
| Project: | Cellular stress in health and disease |
|---|---|
| Supervisors: | Mistrík Martin Ph.D., Moudrý Pavel Ph.D., Škrott Zdeněk Ph.D. |
| Available: | 3 |
| Intended for: | Doctoral training |